HAYA Therapeutics is a precision therapeutics company that discovers and develops innovative tissue- and cell-selective genomic medicines for fibrotic diseases and other serious health conditions associated with aging, including cancer. The company’s discovery engine focuses on long non-coding RNAs (lncRNAs) within the “dark matter” of the human genome to identify novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments.

The company is also developing a pipeline of lncRNA-targeting candidates for the tissue-specific treatment of fibrotic diseases in other tissues, including lungs, kidney, liver, and the micro-environment of solid tumor cancers.